
A Eterna Zentaris
Pharmaceuticals, 315 Sigma Dr, Charleston, South Carolina, 29486, United States, 11-50 Employees
Phone Number: 84********
Who is AETERNA ZENTARIS
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Companys lead product, MacrilenTM (macimorelin), is th...
Read More

-
Headquarters: 315 Sigma Dr, Charleston, South Carolina, 29486, United States
-
Date Founded: 1990
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 7389
Does something look wrong? Fix it. | View contact records from AETERNA ZENTARIS
AEterna Zentaris Org Chart and Mapping
Similar Companies to AEterna Zentaris
Editas Medicine
-
201-500
-
$ 10 Million to 25 Million
Humacyte
-
51-200
-
$ 25 Million to 50 Million
NextPharma
-
1001-5000
-
$ 25 Million to 50 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding AEterna Zentaris
Answer: AEterna Zentaris's headquarters are located at 315 Sigma Dr, Charleston, South Carolina, 29486, United States
Answer: AEterna Zentaris's phone number is 84********
Answer: AEterna Zentaris's official website is https://zentaris.com
Answer: AEterna Zentaris's revenue is $1 Million to $5 Million
Answer: AEterna Zentaris's SIC: 7389
Answer: AEterna Zentaris has 11-50 employees
Answer: AEterna Zentaris is in Pharmaceuticals
Answer: AEterna Zentaris top competitors include: Editas Medicine , Humacyte , NextPharma
Answer: AEterna Zentaris contact info: Phone number: 84******** Website: https://zentaris.com
Answer: Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Companys lead product, MacrilenTM (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). MacrilenTM is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month